VitaNova Life Sciences Corporation VNOV
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 321.60K | 1.78M | 709.60K | 427.10K | 103.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 321.60K | 1.78M | 709.60K | 427.10K | 103.90K |
| Cost of Revenue | 291.10K | 1.52M | 393.30K | 166.30K | 35.10K |
| Gross Profit | 30.50K | 264.70K | 316.30K | 260.80K | 68.80K |
| SG&A Expenses | 152.70K | 374.50K | 269.60K | 161.60K | 101.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 443.70K | 1.89M | 662.90K | 327.90K | 136.30K |
| Operating Income | -122.20K | -109.90K | 46.70K | 99.20K | -32.40K |
| Income Before Tax | -122.20K | -107.00K | 46.70K | 99.30K | -32.40K |
| Income Tax Expenses | 900.00 | -124.50K | 91.10K | 63.50K | 13.90K |
| Earnings from Continuing Operations | -123.10K | 17.50K | -44.40K | 35.80K | -46.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -123.10K | 17.50K | -44.40K | 35.80K | -46.30K |
| EBIT | -122.20K | -109.90K | 46.70K | 99.20K | -32.40K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.01 | 0.00 | -0.01 | 0.00 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | 0.00 | 0.01 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | -0.01 | 0.00 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | 0.00 | 0.01 | 0.00 |
| Average Basic Shares Outstanding | 8.34M | 8.34M | 8.34M | 8.34M | 8.34M |
| Average Diluted Shares Outstanding | 8.34M | 8.34M | 8.34M | 8.34M | 8.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |